Lobbying Update: QUEST DIAGNOSTICS INCORPORATED just disclosed $80,000 of lobbying spending

QUEST DIAGNOSTICS INCORPORATED just disclosed $80,000 of lobbying, from Q4 of 2024, in a new Lobbying Disclosure Act filing.

This included lobbying on issues like:

"H.R. 10545 - The Continuing Appropriations and Extensions Act, 2025- Issues related to funding government departments and agencies responsible for health care programs and support for a delay to certain cuts to laboratory payments covered by Medicare. Rules and regulations related to FDA's treatment of certain laboratory developed tests. Issues related to specific, federally-reimbursed drug testing protocols. H.R. 1835- The Saving Access to Laboratory Services Act - Issues related to the treatment of clinical labs in the Medicare program. Rules, regulations and guidance related to the end of the public health emergency and the treatment of Covid testing, pathology and other related issues. Issues related to testing for STDs. Issues related to testing for PFAS. Issues related to the Cancer Moonshot initiative and addressing ways to combat and prevent cancer.
H.R. 10545 - The Continuing Appropriations and Extensions Act, 2025- Issues related to funding government departments and agencies responsible for health care programs and support for a delay to certain cuts to laboratory payments covered by Medicare. Issues related to combatting the syphilis crisis in the United States and its impact on underserved communities. H.R. 4366 - Consolidated Appropriations and Other Extenders Act of 2024 - Issues related to maintaining support for laboratory programs and services for the upcoming fiscal year. H.R. 2882 - Further Consolidated Appropriations Act of 2024 - Issues related to funding of programs promulgated by the Department of Health and Human Services and its agencies, including CMS. Issues related to specific, federally-reimbursed drug testing protocols. H.R. 1835- The Saving Access to Laboratory Services Act - Issues related to the treatment of clinical labs in the Medicare program."

You can find more data on corporate lobbying on Quiver Quantitative.

DGX Insider Trading Activity

DGX insiders have traded $DGX stock on the open market 14 times in the past 6 months. Of those trades, 0 have been purchases and 14 have been sales.

Here’s a breakdown of recent trading of $DGX stock by insiders over the last 6 months:

• MICHAEL E PREVOZNIK (SVP & General Counsel) has traded it 3 times. They made 0 purchases and 3 sales, selling 67,697 shares.
• CATHERINE T. DOHERTY (EVP, Regional Businesses) has traded it 2 times. They made 0 purchases and 2 sales, selling 33,103 shares.
• MICHAEL J DEPPE (SVP, Corp. Controller & CAO) has traded it 6 times. They made 0 purchases and 6 sales, selling 18,755 shares.
• KARTHIK KUPPUSAMY (SVP, Clinical Solutions) has traded it 2 times. They made 0 purchases and 2 sales, selling 3,765 shares.
• MARK E DELANEY (SVP & Chief Commercial Officer) sold 420 shares.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

DGX Hedge Fund Activity

We have seen 368 institutional investors add shares of DGX stock to their portfolio, and 433 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

• PRICE T ROWE ASSOCIATES INC /MD/ added 3,697,500 shares (+2381.6%) to their portfolio in Q3 2024
• MARSHALL WACE, LLP added 811,640 shares (+429.4%) to their portfolio in Q3 2024
• MILLENNIUM MANAGEMENT LLC removed 786,321 shares (-82.9%) from their portfolio in Q3 2024
• NUANCE INVESTMENTS, LLC removed 681,636 shares (-100.0%) from their portfolio in Q2 2024
• AMERICAN CENTURY COMPANIES INC removed 564,730 shares (-19.8%) from their portfolio in Q3 2024
• 8 KNOTS MANAGEMENT, LLC removed 497,612 shares (-100.0%) from their portfolio in Q3 2024
• MIZUHO SECURITIES USA LLC added 442,835 shares (+5168.5%) to their portfolio in Q3 2024

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.